Approved (FDA / EMA)
FDA (U.S.): Withdrawn: approved (April 15, 2014, Tanzeum) for type 2 diabetes in adults; GSK stopped manufacturing and selling it in 2017-2018 for commercial reasons (not safety). It is no longer available.
EMA (EU): Withdrawn: approved (March 2014, Eperzan) for type 2 diabetes in adults; the authorization was withdrawn on October 29, 2018 at GSK's request for commercial reasons.
There is no established standard dose for this case; it is advisable to consult a professional.
Large double-blind trial (Harmony Outcomes): weekly albiglutide reduced cardiovascular events (cardiovascular death, heart attack or stroke) compared with placebo in people with diabetes and cardiovascular disease. Prescription injectable drug.
View the study (study) →Drug · Highest evidence: Very high · 1 finding
⚠️ Prescription drug (injectable).
Information, not medical advice. Prescription drugs require a doctor.
Information, not medical advice. Scientific evidence reflects the quality of the studies.